• Qool Therapeutics

  Participated · Series A · Nov 2017

  Qool Therapeutics is developing a non-invasive targeted temperature management system comprised of a control unit and a delivery tube that delivers micron-sized frozen saline particles to the lungs to cool the heart, brain, and other central organs. The system leverages the lungs’ large surface area and direct blood flow to enable rapid systemic cooling and enhanced delivery of drugs or biologics to the airways. The company positions the technology for indications including cardiac arrest, stroke, traumatic brain injury, myocardial infarction, sepsis, heat stroke, and as a protective adjunct for vascular surgery, among others. Qool says its device is designed to be non-invasive, rapid, and compatible with the flow of patient care. The company will use new funding to complete product development and prepare for first-in-human clinical trials. Qool is based in the Menlo Park/Silicon Valley area, holds a broad patent portfolio (21 allowed/issued and 15 pending U.S. and international patents), and received an award from the Defense Innovation Unit Experimental (DIUx). Qool Therapeutics develops a non-invasive, field-deployable rapid therapeutic hypothermia system intended for targeted temperature management and exercise recovery. The Qool Therapeutics System is designed to deliver aerosolized frozen saline particles to the lungs so that inhalation cools the heart and brain via the lungs' large surface area and later reduces core body temperature. The company aims to provide a direct path to local organ cooling with a device described as rapid and field deployable. Qool was founded by inventor Amir Belson, MD and is led by CEO Beverly Huss. The company closed a seed funding round of undisclosed amount with participation from an angelMD syndicate led by orthopedic surgeon Michael Dillingham. While completing the seed round Qool is conducting early animal studies and has launched a Series A1 financing round.

• Cadence Biomedical

  Participated · Series B · Jun 2015

  Cadence Biomedical makes the Kickstart device, which uses an Exotendon system of pulleys and springs (no motors or batteries) to capture energy during a step and assist stability, leg advancement and gait cues. The device is intended to accelerate recovery to walking for stroke survivors and patients with other neurological conditions. The company says clinical partners report patients reaching new levels of independence and faster rehabilitation outcomes. Cadence will use the new funding to expand its sales, marketing and reimbursement efforts and to grow its clinical footprint. Barry Hix joined as CEO in November, and COO Brian Glaister founded the company in 2007 (originally Empowering Engineering Technologies). Financially, Cadence announced a $1.2 million Series B and has previously received a $1.0 million Department of Defense grant in 2013 and $1.1 million in funding in 2012. Cadence Biomedical develops the Kickstart Walking System, a non-robotic device that uses natural spring tension to capture energy and provide walking assistance. The Kickstart has been on the market since last September and is prescribed by physicians and custom fitted by orthotists. The company plans to use new funding to develop technologies to help amputees learn to walk with their prostheses. Cadence received a $1 million grant from the Department of Defense to advance this work. The company raised $1.1 million in an oversubscribed funding round last year. Cadence was founded in 2007; CEO Brian Glaister is a Seattle entrepreneur and former Technology Commercialization Fellow at the University of Washington’s Center for Commercialization. Cadence Biomedical is a medtech company. According to a regulatory filing dated Feb. 28, 2013 and reported April 12, 2013, the company raised $1.3 million. The financing comprised equity, options and warrants. Forty-eight investors participated in the raise. The filing lists $0 in sales commissions and $0 in finders' fees. The article does not provide details about the company's products, operations, or future plans. No revenue, user, founding‑year, or location information is reported. Cadence Biomedical is a Seattle-based medical device company developing Kickstart, a Kinetic Orthosis that amplifies existing strength to help people with severe disabilities walk. Kickstart uses no motors or batteries; a proprietary tuned system of pulleys and springs captures energy during the beginning of a step and returns it at the right moment to propel the user and lift the leg for the next step. That action can help many people with severe disabilities walk faster and farther, and allow some who would otherwise require wheelchairs to regain strength and coordination. The company says it is committed to helping the 2.3 million Americans who suffer severe mobility impairments. Cadence has been awarded grants from the National Institutes of Health and the Congressionally-Directed Medical Research Program. The recently closed oversubscribed $1.1 million Series A2 will support manufacturing and sales as Cadence releases Kickstart to the market.

No current team members are available.